Copyright 2005 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2005
Scheiman et al1 are to be congratulated for using good science and methodology to study the treatment of convergence insufficiency (CI). Although CI is quite common, with reported rates of prevalence ranging between 2.25% and 8.3%,1 there is a paucity of good studies that compare popular treatment modalities. As such, the pilot study by Scheiman and colleagues does move forward our understanding of the treatment of this disorder. They compared a rather intensive (and relatively expensive) office-based treatment program with both a very minimally intensive program of home exercises and a placebo treatment. Although the number of subjects was small in this pilot study (between 11 and 15 in each of the 3 treatment arms), the authors found that their intensive office-based program worked quite well. Both the home-based treatment and the placebo, however, did not.
Kushner BJ. The Treatment of Convergence Insufficiency. Arch Ophthalmol. 2005;123(1):100-101. doi:10.1001/archopht.123.1.100